Akt activation confers an inferior survival in patients with activated B-cell subtype of diffuse large B-cell lymphoma: a report from The International DLBCL Rituximab-CHOP Consortium Program
Publication
, Conference
Shen, Q; Xu-Monette, ZY; Manyam, GC; Visco, C; Tzankov, A; Cao, X; Deng, L; Montes-Moreno, S; Dybkær, K; Chiu, A; Orazi, A; Zu, Y; Bhagat, G ...
Published in: Clinical Lymphoma Myeloma and Leukemia
June 2015
Duke Scholars
Published In
Clinical Lymphoma Myeloma and Leukemia
DOI
ISSN
2152-2650
Publication Date
June 2015
Volume
15
Start / End Page
S220 / S221
Publisher
Elsevier BV
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3201 Cardiovascular medicine and haematology
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Shen, Q., Xu-Monette, Z. Y., Manyam, G. C., Visco, C., Tzankov, A., Cao, X., … Young, K. H. (2015). Akt activation confers an inferior survival in patients with activated B-cell subtype of diffuse large B-cell lymphoma: a report from The International DLBCL Rituximab-CHOP Consortium Program. In Clinical Lymphoma Myeloma and Leukemia (Vol. 15, pp. S220–S221). Elsevier BV. https://doi.org/10.1016/j.clml.2015.04.096
Shen, Qi, Zijun Y. Xu-Monette, Ganiraju C. Manyam, Carlo Visco, Alexander Tzankov, Xin Cao, Lijuan Deng, et al. “Akt activation confers an inferior survival in patients with activated B-cell subtype of diffuse large B-cell lymphoma: a report from The International DLBCL Rituximab-CHOP Consortium Program.” In Clinical Lymphoma Myeloma and Leukemia, 15:S220–21. Elsevier BV, 2015. https://doi.org/10.1016/j.clml.2015.04.096.
Shen Q, Xu-Monette ZY, Manyam GC, Visco C, Tzankov A, Cao X, et al. Akt activation confers an inferior survival in patients with activated B-cell subtype of diffuse large B-cell lymphoma: a report from The International DLBCL Rituximab-CHOP Consortium Program. In: Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2015. p. S220–1.
Shen, Qi, et al. “Akt activation confers an inferior survival in patients with activated B-cell subtype of diffuse large B-cell lymphoma: a report from The International DLBCL Rituximab-CHOP Consortium Program.” Clinical Lymphoma Myeloma and Leukemia, vol. 15, Elsevier BV, 2015, pp. S220–21. Crossref, doi:10.1016/j.clml.2015.04.096.
Shen Q, Xu-Monette ZY, Manyam GC, Visco C, Tzankov A, Cao X, Deng L, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WWL, Han van Krieken J, Huh J, Ponzoni M, Ferreri AJM, Farnen JP, Møller MB, Winter JN, Piris MA, Medeiros LJ, Young KH. Akt activation confers an inferior survival in patients with activated B-cell subtype of diffuse large B-cell lymphoma: a report from The International DLBCL Rituximab-CHOP Consortium Program. Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2015. p. S220–S221.
Published In
Clinical Lymphoma Myeloma and Leukemia
DOI
ISSN
2152-2650
Publication Date
June 2015
Volume
15
Start / End Page
S220 / S221
Publisher
Elsevier BV
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3201 Cardiovascular medicine and haematology
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences